EGFR Mutations in Cancer: What They Mean for Treatment

EGFR (epidermal growth factor receptor) sits on the outer membrane of cells and is switched on when a growth factor binds to it, triggering a chain of internal signals that tell the cell to grow and divide. This pathway is essential for normal tissue repair and development, but when the EGFR gene is mutated, the receptor can become permanently active even without a growth signal arriving, pushing the cell toward uncontrolled proliferation.

In non-small cell lung cancer, the most common EGFR alterations cluster in the tyrosine kinase domain of the gene. Exon 19 deletions, in which a short stretch of DNA is removed, account for roughly half of EGFR-mutant cases. The L858R point mutation, a single amino acid substitution in exon 21, accounts for most of the remainder. Together these are often called "classical" or "common" EGFR mutations. A smaller but clinically distinct group carries exon 20 insertion mutations, extra genetic material inserted into a different part of the gene; these tumours behave differently and were, until relatively recently, harder to treat with standard EGFR TKIs.

Over time, tumours treated with an EGFR TKI often develop new mutations that restore receptor activity despite the drug — a hallmark of acquired resistance. T790M, a substitution in exon 20 that blocks first- and second-generation TKIs from binding effectively, is the most frequent resistance mechanism after earlier-generation treatment, though other mechanisms, including MET amplification and histologic transformation, also occur.

If your tumour is found to carry an EGFR mutation, it generally means your care team will consider an EGFR TKI as a preferred treatment option rather than starting with chemotherapy, particularly if the cancer is advanced or has spread (metastatic). The specific mutation matters: exon 19 deletions and L858R are managed somewhat differently from exon 20 insertions, which may respond better to newer, insertion-specific therapies.

If you have already been on an EGFR TKI and the cancer starts growing again, your oncologist will likely recommend repeat biomarker testing — sometimes via a new tissue biopsy, sometimes via a blood-based liquid biopsy — to look for resistance mutations such as T790M. Finding a specific resistance mechanism can point toward a next-generation EGFR TKI or a different treatment strategy rather than an immediate switch to chemotherapy.

If your cancer is in the colon, rectum or head and neck region, an EGFR result carries a different meaning: it does not usually determine eligibility for anti-EGFR antibody therapy on its own, but it flags EGFR as a relevant pathway worth discussing with your team, alongside other biomarkers like RAS and BRAF.

EGFR mutation testing is not itself a cancer diagnosis test; it is performed after non-small cell lung cancer (or another EGFR-relevant cancer) has already been diagnosed by biopsy and pathology review, as part of characterising the tumour's molecular profile. The result is reported alongside stage, histology and other biomarkers such as PD-L1 and ALK to build a complete treatment picture. A pathology or molecular report will list the specific EGFR alteration detected, using standard nomenclature (for example "exon 19 deletion" or "L858R"), which your oncologist uses to match you to the most appropriate targeted therapy.

EGFR testing in lung cancer is typically performed on tumour tissue obtained through biopsy or surgery, using next-generation sequencing (NGS) panels that can detect exon 19 deletions, L858R, exon 20 insertions and other rarer variants in a single run. Targeted PCR-based tests are also used, particularly when a fast result is needed or when only common mutations need to be ruled in or out. When tissue is scarce, difficult to obtain safely, or when repeat sampling is needed to check for resistance, a liquid biopsy analysing circulating tumour DNA from a blood sample can detect many EGFR mutations, including T790M, though a negative liquid biopsy does not fully rule out the mutation and tissue testing may still be recommended.

Guidelines recommend EGFR testing for essentially all patients with newly diagnosed advanced or metastatic non-small cell lung adenocarcinoma, and it is increasingly considered even in some squamous or mixed histology cases, particularly in never-smokers. Results usually take one to two weeks depending on the method and laboratory.

In colorectal cancer, EGFR protein expression by immunohistochemistry was used historically, but it does not reliably predict response to anti-EGFR antibodies and has largely been replaced by RAS (KRAS, NRAS) and BRAF mutation testing, which do predict benefit or lack of benefit from these drugs. In head and neck squamous cell carcinoma, EGFR expression is nearly universal, so formal EGFR testing is less central to treatment selection than in lung cancer.

EGFR mutations are most clinically significant in non-small cell lung cancer, particularly adenocarcinoma, where they are found in a meaningful minority of cases overall and considerably more often in patients who have never smoked, in women, and in people of East Asian ancestry. Within NSCLC, exon 19 deletions and L858R are the classical mutations driving first-line EGFR TKI use, while exon 20 insertions form a smaller subgroup historically resistant to standard EGFR TKIs but now addressed by newer, insertion-specific agents.

Outside lung cancer, EGFR is relevant in colorectal cancer, where the receptor is a target of monoclonal antibody therapy, although as noted, treatment selection there depends primarily on RAS and BRAF mutation status rather than EGFR expression level. EGFR is also highly relevant in head and neck squamous cell carcinoma, where EGFR-targeted antibody therapy has an established role in combination with radiotherapy or chemotherapy in various settings. Rarer EGFR alterations, including amplification, are also studied in glioblastoma and other tumour types, though targeted therapy in those settings is less established.

EGFR-targeted therapies are generally described in generations. First-generation EGFR TKIs reversibly block the receptor and were the original standard of care for classical EGFR mutations. Second-generation EGFR TKIs bind more tightly and irreversibly, offering broader activity against some uncommon mutations but often with more gastrointestinal and skin-related side effects. Third-generation EGFR TKIs were designed specifically to remain effective against T790M-resistant tumours while sparing normal EGFR in healthy tissue, and one such agent is now widely used as an initial treatment option for classical mutations as well as after resistance develops, depending on individual circumstances.

For exon 20 insertion mutations, dedicated inhibitors and an antibody-based option have been developed because older TKIs are often less effective against this subgroup; the choice depends on prior treatment, specific insertion variant, and how the disease is behaving. When resistance emerges on any EGFR TKI, options include switching to a different-generation TKI matched to the newly identified resistance mutation, combination strategies pairing targeted therapy with other agents, or transitioning to chemotherapy, sometimes with immunotherapy, especially if no actionable resistance mechanism is found.

In colorectal cancer, anti-EGFR monoclonal antibodies are used in combination with chemotherapy for RAS/BRAF wild-type metastatic disease. In head and neck cancer, an EGFR-targeted antibody may be combined with radiotherapy for locally advanced disease or with chemotherapy in the recurrent or metastatic setting. Across all these situations, clinical trials continue to test new EGFR-directed combinations and next-generation agents, and asking about trial eligibility is a reasonable part of any discussion about treatment options.